RxDoctor Payments Data

Joan Dutton

Acute Care · Carthage, MONPI 1336494319

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.0% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Abbott at 41.3% of the total.

$1,673in general payments, 2019–2025

Across 50 payments — averaging $33.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$690
  • Abiomed$133
  • Novartis$126
  • Bayer$117
  • Boehringer Ingelheim$102
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$85
  • plus $420 from 12 others

What the payments were for

  • Travel & lodging$1348%
  • Food & beverage$1,53992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,673 in reported general payments places this provider in the 80th percentile of 272 acute care providers in Missouri.

See all acute care providers in Missouri

Medicare billing

Part B allowed, 2024
$44,265
Medicare patients
219
Services billed
550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan86$79,468
JardianceEmpagliflozin87$73,136
EliquisApixaban24$14,472
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,095
Torsemide67$942
Spironolactone140$551
Bumetanide20$519
Metoprolol Succinate80$376
Levothyroxine Sodium23$321
Pantoprazole Sodium20$286
Potassium Chloride29$253
Furosemide60$215
Atorvastatin Calcium22$171
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen21$137
Carvedilol39$101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$126$79,46886 claims
Boehringer IngelheimJardiance$102$73,13687 claims
PfizerEliquis$37$14,47224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 272 acute care providers in Missouri.

Other acute care in Carthage

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →